Effect of Oral NAD+ Precursors Administration on Blood NAD+ Concentration in Healthy Adults

Inclusion criteria

• Healthy male and female aged 18-50 years, inclusive, at enrolment
• Body mass index (BMI) between 18.5 to 27.0 kg/m².
• Able to understand and to sign a written informed consent prior to study enrolment.
• Willing and able to comply with the requirements for participation in this study.

Exclusion criteria

• Known history of allergy or intolerance to the investigational products.
• Any chronic medical condition and/or history of significant medical condition, which in the opinion of the site physician/ investigator may risk participant wellbeing/ safety, impede participant compliance with study procedures or ability to complete the study and/ or could confound the primary objectives of the study.
• Any acute illness or any recent medical intervention including vaccination within 14 days before the first dose of investigational product.
• Female participants who are pregnant or intending to become pregnant, lactating and/or breastfeeding. Women of childbearing potential who are not currently using medically effective forms of contraception.
• Use of prescription drugs known to potentially interact with NAD precursors within 14 days or 5 half-lives (whichever is longer) prior to the first dose of investigational product.
• Use of multivitamin/ multimineral supplements, NAD+ precursor supplementation (e.g., niacin, nicotinic acid or niacinamide), L-tryptophan supplementation and/ or any over-the- counter (OTC) medication promoting "healthy aging" or "anti-aging" or "longevity" up to 30 days before first dose of investigational product.
• On a self-restricted diet, controlled diet or special therapeutic diet up to 30 days before first dose of investigational product.
• Average alcohol consumption greater than 2 standard drinks per day over a week for males, and greater than 1 standard drink per day over a week for females. One standard drink contains 10-12 g of ethanol. Examples of standard drinks are one beer can (300 ml), one glass of wine (100 ml) or one glass of schnaps (30 ml).
• Current smoker (e.g., cigarette, tobacco, cannabis) who exceeds 5 cigarettes per week.
• Performing shift work or trans-meridian travel greater than two time zones within 14 days prior to the first dose of investigational product.
• Currently participating in another research study.
• Family or hierarchical relationships with the Clinical Innovation Lab (CIL) team.